Abstract
In spite of the marded improvements of pharmacokinetic and pharmacodynamic characteristics of currently available rapid acting insulins, their profiles are still significantly different from the endogenous insulin secretion. Therefore, there is still an unmet need for insulins with a more rapid onset of action.
Owing to a modified composition of the injection solution, fast-acting insulin aspart (Fiasp) has more favourable pharmacokinetic and pharmacodynamic properties as compared to standard insulin aspart or other rapid acting insulin analogues. As a result, insulin Fiasp has more rapid onset of action and more pronounced reduction of postprandial hyperglycaemia in patients with both type 1 and type 2 diabetes.
The present article summarises current insights in the pharmacokinetics and pharmacodynamics of insulin Fiasp and its clinical efficacy and safety in patients with type 1 and type 2 diabetes. The results from published studies suggest that insulin Fiasp has a potential to further improve postprandial hyperglycaemia in patients with type 1 or type 2 diabetes when administered both as a part of intensified insulin therapy or by an insulin pump.